Intraocular Melanoma: Clinical Trials

19 trials for Intraocular Melanoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed, 2 unknown, 1 terminated. 19 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 219Completed 16, Unknown 2, Terminated 1
Phase 13Completed 3

Follow Intraocular Melanoma: new trials by email Literature Review of Intraocular Melanoma trials Research Report on Intraocular Melanoma

Trials (filtered) newest first · largest first

All 19 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye
bevacizumab, temozolomide, polymorphism analysis - Intraocular Melanoma
Phase 2UnknownInstitut Curie352009-10-012013-08-26
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery
nab-paclitaxel - Intraocular Melanoma
Phase 2CompletedOhio State University Comprehensive Cancer Center42008-08-012016-02-12
Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
cisplatin, sunitinib malate, tamoxifen citrate - Intraocular Melanoma
Phase 2UnknownSan Diego Pacific Oncology & Hematology Associates502007-05-012014-01-10
Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
cyclophosphamide, lenalidomide, sunitinib malate - Intraocular Melanoma, Malignant Conjunctival Neoplasm
Phase 2TerminatedNational Institutes of Health Clinical Center (CC)122007-04-012017-03-27
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
DNA analysis, immunologic technique, pharmacological study - Brain and Central Nervous System Tumors, Intraocular Melanoma
Phase 2CompletedMemorial Sloan Kettering Cancer Center782006-01-012024-04-04
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
cediranib maleate - Acral Lentiginous Malignant Melanoma, Ciliary Body and Choroid Melanoma, Medium/Large Size
Phase 2CompletedNational Cancer Institute (NCI)242006-01-012018-08-27
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
ipilimumab, Tyrosinase/gp100/MART-1 Peptides - Intraocular Melanoma, Melanoma (Skin)
Phase 2CompletedBristol-Myers Squibb772004-05-312022-04-14
Vaccine Therapy in Treating Patients With Metastatic Melanoma
MART-1 antigen, gp100:209-217(210M) peptide vaccine, therapeutic autologous dendritic cells - Intraocular Melanoma, Melanoma (Skin)
Phase 2CompletedUniversity of Southern California62003-10-012014-05-21
Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma
lomustine, temozolomide, thalidomide - Intraocular Melanoma, Melanoma (Skin)
Phase 2CompletedMemorial Sloan Kettering Cancer Center2003-07-012013-01-18
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
IFA, 6MHP, GM-CSF - Intraocular Melanoma, Melanoma (Skin)
Phase 1 / Phase 2CompletedUniversity of Virginia392003-07-012014-11-20
Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
aldesleukin, ipilimumab - Intraocular Melanoma, Melanoma (Skin)
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)2003-02-012013-06-20
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, sargramostim - Intraocular Melanoma, Melanoma (Skin)
Phase 2CompletedUniversity of Virginia72002-08-012014-12-19
Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant - Intraocular Melanoma, Melanoma (Skin)
Phase 2CompletedUniversity of Southern California602002-02-012014-05-22
Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
gp100 antigen, incomplete Freund's adjuvant, ipilimumab - Intraocular Melanoma, Melanoma (Skin)
Phase 2CompletedNational Cancer Institute (NCI)2002-01-012013-06-20
Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma
pegylated interferon alfa, temozolomide - Intraocular Melanoma, Melanoma (Skin)
Phase 2CompletedMemorial Sloan Kettering Cancer Center2001-05-012013-06-05
PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma
PEG-interferon alfa-2b, thalidomide - Intraocular Melanoma, Melanoma (Skin)
Phase 2CompletedBarbara Ann Karmanos Cancer Institute322001-01-012013-04-08
Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma
temozolomide, thalidomide - Intraocular Melanoma, Melanoma (Skin)
Phase 1 / Phase 2CompletedMemorial Sloan Kettering Cancer Center1999-12-012013-06-19
Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma
pyrazoloacridine - Intraocular Melanoma, Melanoma (Skin)
Phase 2CompletedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins1999-02-012012-12-17
Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma
gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-12 - Intraocular Melanoma, Melanoma (Skin)
Phase 2CompletedUniversity of Southern California481998-11-012014-05-22

Narrower conditions

Uveal Melanoma (19)  ·  Melanoma (15)  ·  Astrocytoma (1)  ·  Brain Neoplasms (1)  ·  Central Nervous System Neoplasms (1)  ·  Chondrosarcoma (1)  ·  Desmoplastic Small Round Cell Tumor (1)  ·  Ependymoma (1)  ·  Familial ependymoma (1)  ·  Glioblastoma (1)  ·  Glioma (1)  ·  Glioma, Subependymal (1)  ·  Gliosarcoma (1)  ·  Lung Neoplasms (1)  ·  Medulloblastoma (1)

Broader conditions

Eye Diseases (19)  ·  Eye Neoplasms (19)  ·  Neoplasms (19)  ·  Neoplasms by Histologic Type (19)  ·  Neoplasms by Site (19)  ·  Neoplasms, Germ Cell and Embryonal (19)  ·  Neoplasms, Nerve Tissue (19)  ·  Neuroectodermal Tumors (19)  ·  Neuroendocrine Tumors (19)  ·  Nevi and Melanomas (19)  ·  Uveal Diseases (19)  ·  Uveal Neoplasms (19)  ·  Skin Diseases (15)  ·  Skin Neoplasms (15)  ·  Skin and Connective Tissue Diseases (15)

Interventions

incomplete Freund's adjuvant (5)  ·  Temozolomide (4)  ·  Ipilimumab (3)  ·  Thalidomide (3)  ·  sargramostim (3)  ·  Chemotherapy, Adjuvant (2)  ·  Interleukin-12 Subunit p35 (2)  ·  MART-1 Antigen (2)  ·  Sunitinib (2)  ·  130-nm albumin-bound paclitaxel (1)  ·  Albumin-Bound Paclitaxel (1)  ·  Aluminum Hydroxide (1)  ·  Amplified Fragment Length Polymorphism Analysis (1)  ·  Bevacizumab (1)  ·  Cisplatin (1)

Sponsors

Memorial Sloan Kettering Cancer Center (4)  ·  National Cancer Institute (NCI) (3)  ·  University of Southern California (3)  ·  University of Virginia (2)  ·  Barbara Ann Karmanos Cancer Institute (1)  ·  Bristol-Myers Squibb (1)  ·  Institut Curie (1)  ·  National Institutes of Health Clinical Center (CC) (1)  ·  Ohio State University Comprehensive Cancer Center (1)  ·  San Diego Pacific Oncology & Hematology Associates (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)

Countries

United States (17)  ·  Canada (1)  ·  France (1)

Top investigators

Jeffrey S. Weber, MD, PhD (3)  ·  Wen-Jen Hwu, MD, PhD (3)  ·  Craig L. Slingluff, MD (2)  ·  Steven A. Rosenberg, MD, PhD (2)  ·  Edward F. McClay, MD (1)  ·  Elaine McWhirter (1)  ·  Kim Kramer, MD (1)  ·  Sophie Piperno-Neumann, MD (1)  ·  Steven K. Libutti, MD (1)  ·  Thomas E. Olencki, DO (1)  ·  Ulka N. Vaishampayan, MD (1)  ·  William H. Sharfman, MD (1)

Results publications

PMID 25667295, PMID 12039921, PMID 12826605, PMID 12947072, PMID 16087944, PMID 16283570, PMID 18809608, PMID 21106722, PMID 25126421, PMID 28851380, PMID 32161584

NIH funding

N01CM62201 (1), N01CM62203 (1), P30CA006973 (1), P30CA008748 (1), P30CA014089 (1), P30CA022453 (1), P30CA076292 (1), U01CA063437 (1)